# Life Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/life-biosciences

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.lifebiosciences.com
- Total disclosed funding: $132M
- Latest round: Series C (Jan 5, 2022)
- Investors on record: 3

## About

Based in Massachusetts, US, and founded in 2017, Life Biosciences Inc., a.k.a. Life Biosciences operates as a life sciences company that focuses on discovering and developing novel therapies to improve the lives of people as they age. In January 2022, Life Biosciences Inc. raised USD 82 million in a Series C funding led by Alpha Wave Global. As of May 2024, Jerry McLaughlin is the CEO of the company.

The company leverages its partial epigenetic reprogramming platform to reprogram the epigenome to resemble that of younger animals using Yamanaka factors, demonstrating success in restoring vision and nerve regeneration in preclinical models. Life Biosciences also utilizes a chaperone-mediated autophagy platform that enhances the degradation of unwanted proteins by increasing the expression of proteins like LAMP2A, showing efficacy in models of frontotemporal dementia, Alzheimer’s disease, and retinal degeneration. These approaches enable Life Biosciences to address unmet medical needs in aging-related diseases.

## Funding rounds

- Series C, Jan 5, 2022, $82M — Alpha Wave Global, Gaingels
- Series B, Jan 15, 2019, $50M — LeFrak

## Investors

- LeFrak (https://capitalatlas.ai/funds/lefrak) — Series B
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series C
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series C